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Abstract
Bowel endoscopy referrals from primary care have increased steadily over recent years. However, most patients do
not have significant colorectal disease (SCD). Therefore, strategies to select those who would benefit most from
endoscopy are of current interest. A recent study developed a multivariable diagnostic model for SCD with routine
clinical information, extended with quantitative faecal calprotectin (f-C) point-of-care (POC) testing and/or qualitative
POC faecal immunochemical test (FIT) for haemoglobin (f-Hb) results. This study used POC tests for both f-C and f-Hb;
however, POC tests have many disadvantages and there are several reasons why quantitative measurements of f-Hb
are advantageous. Quantitative faecal immunochemical tests have been used very successfully in triage of patients
presenting in primary care as a rule-out test. Studies have compared f-C and f-Hb in this clinical context and consider
that f-C is not required in diagnosis. A single quantitative f-Hb result, without any clinical information, could be
sufficient to decide whom to refer for endoscopy and, because of the significant overlap of symptoms in those
with and without SCD, could be the primary investigation performed.
Please see related article: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0684-5.
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Background
The number or requests for lower gastrointestinal en-
doscopy has continued to increase in recent years, partly
due to the success of colorectal cancer (CRC) screening
programmes and the surveillance of greater number of
patients with known and treated disease, but mainly due
to referrals from primary care to investigate patients
with lower abdominal symptoms. As documented by
Elias et al. [1], the majority of these patients do not have
significant colorectal disease (SCD) and are unnecessarily
exposed to an unpleasant and invasive procedure that
carries a small, but realistic, risk of complications.
Therefore, and considering the very limited endoscopy
resources in several countries, strategies to select those
patients who would benefit most from endoscopy are of
considerable interest, as exemplified by the work under way
by the National Institute for Health and Care Excellence
(NICE) on quantitative faecal immunochemical tests (FITs)
to assess symptomatic people presenting in primary care
who are at low risk of CRC [2].
Faecal tests and triage strategies in patients with lower
abdominal symptoms
Elias et al. [1] used data from a prospective diagnostic
study in patients from primary care practices with per-
sistent lower abdominal symptoms referred for endoscopy
to develop a multivariable diagnostic model for SCD with
routine clinical information, which was extended with
quantitative faecal calprotectin (f-C) point-of care (POC)
test data and/or qualitative POC FIT for haemoglobin
(f-Hb) results. SCD was defined as CRC, inflammatory
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bowel disease, diverticulitis or advanced adenoma
(simplistically, as those above 1 cm in diameter) de-
tected at endoscopy. Of 810 patients, 141 (17.4 %) had
SCD, supporting the “rule of sixths” that one-sixth of
patients presenting in primary care have SCD, two-
sixths have other, less significant bowel disorders, and
three-sixths have a normal colon on endoscopy [3].
This study used POC tests for both f-C and f-Hb, the
rationale being that these can be easily executed at the
time and place of patient care. However, POC tests have
several disadvantages – currently available POC FITs have
considerable differences with regard to their analytical de-
tection limit [4]. Therefore, the conclusions of Elias et al.
[1] may not be applicable to other POC FITs with varying
analytical sensitivity and specificity. Moreover, faecal spe-
cimen collection is problematic since f-Hb is unstable, as
confirmed by Elias et al. [1], requiring the use of simple
and hygienic specimen collection devices rather than the
traditional “stool pots”. Further, the colour development
on immunochromatographic POC tests is very dynamic
and early or late reading will lead to false negative or false
positive results, respectively. Therefore, the results are not
easy to interpret, especially when borderline positive, un-
less performed following adequate training and in good
light, and preferably by those with good visual acuity.
Thus, there are several reasons why high-quality quantita-
tive measurements of f-Hb performed in ISO 15189 accre-
dited laboratories are much preferred. As discussed by
Elias et al. [1], these FITs have now been used very suc-
cessfully in triage of symptomatic patients presenting in
primary care and allow improved diagnostic information
to be gained. However, it might be that use of central
laboratory-based tests would cause some, albeit small,
delay in diagnosis and, more importantly, some drop out
and loss of patients from pathways after presentation. It
would be of interest to undertake an objective comparison
of the efficiency and effectiveness of POC as compared to
central laboratory testing.
Elias et al. [1] demonstrated that a diagnostic model
with routine clinical data discriminated between patients
with and without SCD with an area under the receiver
operating characteristic curve (AUC) of 0.741. This AUC
increased to 0.763 when adding the f-C and to 0.831
when adding the f-Hb, and to 0.837 upon combined ex-
tension; 30.4 % of the patients tested negative based on
this combined POC test extended model, with a 96.4 %
negative predictive value (NPV). This high NPV indi-
cates that this approach is a good rule-out test for SCD.
However, excluding the f-C from this model still yielded
96.0 % NPV. It was concluded that a diagnostic strategy
with routine clinical data and f-Hb alone may safely rule
out SCD and prevent unnecessary endoscopy referral in
approximately one-third of patients. Interestingly, there
are other studies which have compared f-C and f-Hb in
this clinical context [5, 6], and they too consider that f-C
is not required. Patients with SCD have higher concen-
trations of f-Hb, since f-Hb is related to the severity of
colorectal disease [7], and there is now much evidence
that f-Hb alone has huge potential for use in risk strati-
fying of symptomatic patients. Indeed, there is growing
evidence that f-Hb is more useful than f-C in the assess-
ment and monitoring of ulcerative colitis [8]. Thus, per-
haps in the near future, when quantitative f-Hb becomes
more widely available for triage of symptomatic patients,
f-C will be used mainly in the monitoring of patients
with known inflammatory bowel disease rather than in
the diagnostic setting. Further research is needed to
compare f-C and f-Hb in a wide range of gastrointestinal
disorders.
There is much evidence that a single f-Hb result could
be sufficient to decide whom to refer for endoscopy [9].
Indeed, Elias et al. [1] state that their results also under-
score that a positive f-Hb already implies the need for
referral and admit that the clinical data do not add
much. However, it was suggested that such data are in-
formative when the f-Hb result is negative. Moreover, it
was alleged that, in daily clinical practice, and certainly
in primary care, it is rare that primary healthcare profes-
sionals would immediately request tests in patients pre-
senting with symptoms and signs of SCD without even
considering any other pre-test diagnostic information
from history taking and physical examination. It was ar-
gued that the diagnostic process in primary care is sequen-
tial, starting with history taking and physical examination,
with follow-up testing only in cases where these provide
indications that support additional testing. Thus, in order
to ensure adherence to primary care practice, Elias et al.
[1] explicitly initially evaluated the diagnostic value of his-
tory taking, physical examination, and simple blood testing
and, subsequently, the added value of the POC f-Hb, ra-
ther than in reverse. However, the introduction to the
work of Elias et al. [1] and to this commentary both indi-
cate that, although lower abdominal symptoms are very
common presenting complaints, SCD is rarer. Because of
the significant overlap of symptoms in those with and
without SCD, it could be argued that, because f-Hb is such
a good rule-out test for SCD, this should be the primary
and first investigation to be performed.
Conclusions
Deciding which patients presenting with lower abdominal
symptoms will benefit most from endoscopy is prob-
lematic. Combined faecal biomarkers, such as f-C and
f-Hb, have been advocated, but f-Hb alone has advan-
tages. Qualitative estimates of f-Hb also provide more
information than qualitative f-Hb POC tests. Simple
and rapid diagnostic pathways are also advantageous.
Thus, a possible strategy would be to collect a sample
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for qualitative measure of f-Hb from all patients presenting
with lower abdominal symptoms in primary care. Following
this, senior endoscopy staff could assess, taking the f-Hb re-
sults and symptoms into account, whether there is a need
for the patient to undergo endoscopy. Nevertheless, there
are, of course, other alternative strategies and it is hoped
that future research will explore the best applications of
f-Hb in the triage of the symptomatic, although these
might be highly dependent on local circumstances and
approaches.
Author’s information
CGF is currently Senior Research Fellow, Scottish Bowel Screening Research
Unit; Honorary Professor, Centre for Research into Cancer Prevention and
Screening, University of Dundee; and Honorary Consultant Clinical Biochemist,
NHS Tayside. Over the last 15 years, he has been heavily involved in the
development and assessment of colorectal cancer screening programmes,
and the use of faecal tests in diagnosis of colorectal disease.
Competing interests
CGF undertakes paid consultancy with Immunostics Inc., Ocean, NJ, USA, and
Kyowa-Medex Co., Ltd, Tokyo, Japan, and has received support for travel and
attendance at conferences from Alpha labs Ltd., Eastleigh, Hants, UK.
Received: 20 August 2016 Accepted: 14 September 2016
References
1. Elias SG, Kok, L, de Wit, NJ, Witteman BJM, Goedhard G, Romberg-Camp MLJ,
et al. Is there an added value of faecal calprotectin and haemoglobin in the
diagnostic work-up for primary care patients suspected of significant
colorectal disease? A cross-sectional diagnostic study. BMC Med. 2016.
doi: 10.1186/s12916-016-0684-5
2. National Institute for Health and Care Excellence (NICE). Quantitative faecal
immunochemical tests to assess symptomatic people who are at low risk of
colorectal cancer in primary care. https://www.nice.org.uk/guidance/
indevelopment/gid-dg10005. Accessed 18 Aug 2016.
3. Fraser CG. Investigating Bowel Symptoms: Remember the Rule of Sixths.
https://scpnblog.wordpress.com/2015/06/12/investigating-bowel-symptoms-
remember-the-rule-of-sixths/. Accessed 18 Aug 2016.
4. Tao S, Seiler CM, Ronellenfitsch U, Brenner H. Comparative evaluation of
nine faecal immunochemical tests for the detection of colorectal cancer.
Acta Oncol. 2013;52(8):1667–75.
5. Mowat C, Digby J, Strachan JA, Wilson R, Carey FA, Fraser CG, Steele RJ.
Faecal haemoglobin and faecal calprotectin as indicators of bowel disease
in patients presenting to primary care with bowel symptoms. Gut. 2016;
65(9):1463–9.
6. Thomas CL, Tomkins C, Widlak M, Smith S, Arasaradnam R. Can
immunochemical tests for faecal haemoglobin and faecal calprotectin be
used to risk stratify patients for referral to colonoscopy for suspected
colorectal cancer? Ann Clin Biochem. 2016;53 Suppl 1:38–9. http://acb.
sagepub.com/content/suppl/2016/04/07/53.3.DC1/Posters_to_be_
displayed_Tuesday_p23-48.pdf Accessed 18 Aug 2016.
7. Digby J, Fraser CG, Carey FA, McDonald PJ, Strachan JA, Diament RH, et al.
Faecal haemoglobin concentration is related to severity of colorectal
neoplasia. J Clin Pathol. 2013;66(5):415–9.
8. Hiraoka S, Kato J, Nakarai A, Takashima S, Inokuchi T, Takei D, et al.
Consecutive measurements by faecal immunochemical test in quiescent
ulcerative colitis patients can detect clinical relapse. J Crohns Colitis. 2016;
10(6):687–94.
9. Fraser CG, Strachan JA. A nicer approach to the use of ‘faecal occult
blood tests’ in assessment of the symptomatic. Ann Clin Biochem. 2016;
53(Pt 1):5–6.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Fraser BMC Medicine  (2016) 14:139 Page 3 of 3
